


"Exceptional quality healthcare for all through equitable access, excellent experience and optimal outcomes"



REDUCING HEALTHCARE INEQUALITIES








National Prostate Cancer Audit State of the Nation Report


An audit of the care received by men diagnosed with prostate cancer in England and Wales from 01/01/2019 to 31/12/2023


Published January 2025





Infographic for England and Wales





Disease presentation

For men diagnosed between January - December 2021 in England and between April 2022 - March 2023 in Wales

17%^E of men presented with metastatic disease in England (E) and Wales (W)




Figure 3. Annual number of men newly diagnosed with prostate cancer by age-ethnicity-deprivation group Data for England from 1st January 2021 to 31st December 2023¹¹.

6






Figure 4. Annual number of new diagnoses per 1000 male population by age-ethnicity-deprivation group Data for England from 1st January 2021 to 31st December 2023¹².

7

Diagnosis and treatment by age-ethnicity-deprivation



Treatment allocation



Treatment outcomes




Figure 8. Percentage of white and black men with high-risk/ locally advanced cancer who received radical treatment, by age (in England, 1st January 2020 to 31st December 2021¹⁶).





Figure 9. Percentage of men with high-risk/locally advanced cancer who received radical treatment, by Index of Multiple Deprivation fifth by age (in England, 1st January 2020 to 31st December 2021¹⁶).



10

Inequalities in prostate cancer treatment

Black men aged 55 to 70 years were less likely to receive radical treatment than white men.

Men living in more deprived areas had lower treatment rates than those in less deprived areas.

Geographic inequality within the UK exists too.

In Yorkshire and the North East, 20.5% of patients had metastases at the time of presentation, compared with 12.5% of those in London.

CORE20 PLUS 5

Health Inequalities Improvement Policy Drivers:

- The NHS Constitution
- 2022 Health and Care Act
- The NHS Long Term Plan
- NHS England Priorities & Planning Guidance
- Government Mandate to the NHS
- Levelling up White Paper
- Digital Health and Care Plan
- Covid19 Elective Recovery Plan
- High Intensity User Programme
- Ten Year Plan

CORE20 PLUS 5 Evidence into practice

	total spending on		85%
	COVID-19 vaccine programme by the October 2021 (inc procurement cost UK and deployme for England)	e vaccine doses e end of administered in England by cluding the end of October 2021 is for the	proportion of people aged 18 and over in England who had received two doses of COVID-19 vaccine by the end of October 2021, compared with a planning assumption of 75%
	More than 340 million	or agreed to purchase by the	9 vaccine the UK had contracted end of October 2021, for deliver
	710/2		cinations administered by GPs
	7190	and community pharmacies up to the end of October 2021,	
		contractor instanti at estatuto	
	£2.9 billion		D-19 vaccines for the UK up to t of a total spend of £3.3 billion b
		the Vaccine Taskforce	
Department for Business, Energy & Industrial Strategy	£2.2 billion	total spent on COVID-19 vaccine distribution and deployment in England to the end of October 2021	
	4.0%	estimated percentage of CO	VID-19 vaccine doses damaged o
		not used in England ('wastage') up to the end of October 202 against a planning assumption of 15%-20%	
REPORT	48%-86%		s vaccinated with two doses by
by the Comptroller			ctober 2021 (48% for people of r people of White British origin)
	£8.3 billion	total funding available for the	COVID-19 vaccination
SESSION 2021-22 25 FEBRUARY 2022		그 같은 것 같은 것 않았다. 그는 것 같은 것 같은 것 같이 가 가 있었다. 것 같아요. 그는 것 않는 것 같아요. 그는 그는 것 같아요. 그 그 그 그 요. 그 그 그 그 요. 그 그 요. 그 그 그 그	March 2022, consisting of , primarily to purchase vaccines,
	REPORT by the Comptroller and Auditor General SESSION 2021-22	More than 340 million 71% £2.9 billion £2.9 billion £2.2 billion 4.0% 4.0% 88%–86% by the Comptroller and Auditor General \$ESSION 2021-22	More than 340 million number of doses of COVID-1 or agreed to purchase by the by the end of 2022 71% percentage of COVID-19 vac and community pharmacies u against an initial planning as: £2.9 billion total spent to purchase COV the end of October 2021, out the Vaccine Taskforce £2.2 billion total spent on COVID-19 vac in England to the end of October 4.0% estimated percentage of COV not used in England (wastag against a planning assumption the Comptroller and Auditor General ESSION 2021-22 £8.3 billion ESSION 2021-22 £8.3 billion

https://www.nao.org.uk/wp-content/uploads/2022/02/The-rollout-of-the-COVID-19-vaccination-programme-in-England.pdf

Kov facte






Encouraging black men to prioritise prostate cancer checks

12th February 2025

Prostate cancer disproportionately affects black men, who are twice as likely to be diagnosed with the disease compared to other groups. Early detection saves lives, but cultural barriers and a lack of open conversations can delay vital health checks. The short film, Embarrassed, featuring an incredible line-up of black male actors, delivers a powerful message to get checked and start the conversation. By breaking the taboo, we can encourage more men to prioritise their health.





Live Bollywood music from Sur Sangeet from India

For more information website www.sahauk.org or email us for assistance. Email: connectors@sahauk.org WhatsApp: Contact Kirit at 07940516666.

As the event is free, we encourage everyone to come on time to enjoy the festivities to the fullest.

We look forward to seeing you on this South Asian Health Awareness Event, not to be missed.



5 Key Recommendations

National Prostate Cancer Audit State of the Nation Report

- 1. Aim to achieve high completeness of key data items at the point of collection
- 2. Continue to advocate active surveillance for men with low-risk prostate cancer
- 3. Investigate why men with high-risk/locally advanced disease are not considered for **radical treatment** and aim to reduce that population
- 4. Review variation between providers in rates of genitourinary/gastrointestinal **complications** and 90-day readmission rates
- 5. Decisions regarding treatment should consider life expectancy and co-morbidity, balancing the treatment benefits and risks, to ensure **equitable care**